Walleye Capital Adds $5M in Aurinia Pharmaceuticals Inc. ($AUPH)
Key Points
- Walleye Capital changed its Aurinia Pharmaceuticals Inc. ($AUPH) stake by 1303.9% last quarter, boosting to 321,567 shares worth $5.09 million.
- $AUPH last traded around $15.82.
Walleye Capital increased its position in Aurinia Pharmaceuticals Inc. ($AUPH) by 1303.9% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 321,567 shares of Aurinia Pharmaceuticals Inc. after buying 298,662 shares during the quarter. Walleye Capital's holdings in Aurinia Pharmaceuticals Inc. were worth $5.09 million as of its most recent filing.
Aurinia Pharmaceuticals Inc. ($AUPH) Stock
Aurinia Pharmaceuticals Inc. Earnings
Analysts Set New Price Targets
About Aurinia Pharmaceuticals Inc.
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.